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A B S T R A C T
Despite advances in antiepileptic drug (AED) therapy, about one-third of patients with epilepsy are resistant to drug
treatment. Functional impact of polymorphisms in drug-efflux transporter genes may contribute to multidrug resistance
theory. Studies on ABCB1 gene gave contradictory results and available data suggest that this polymorphism may not
directly cause altered P-glycoprotein (Pgp) transport activity but may be associated with one or more causal variants in
the stretch of linkage disequilibrium or is caused by multiple gene polymorphisms. Genetic polymorphisms also occur
frequently in other transmembrane transport systems including the multidrug resistance proteins (MRPs, ABCC2). The
aim of this research was to investigate the possible association of ABCC2 gene polymorphisms G1249A in exon 10 and
C24T in exon 1 with the development of drug resistance. This cross-sectional study is a part of ongoing pharmacoge-
nomic study of epilepsy in Croatian population. All patients enrolled in the study had an established diagnosis of partial
complex epilepsy with or without secondary generalization with non lesional brain MRI with epilepsy protocol and have
been suffering for more than two years. They were divided into two groups. The first group comprised 52 patients refrac-
tory to the current therapy, while the second group consisted of 45 patients with well-controlled seizures. Our data did
not identify any significant association between genetic polymorphisms of exon 1 (24C>T) and exon 10 (1249G<A) of
ABCC2 gene or any combined effect in response to AED treatment and development of drug resistance in patients with
partial complex epilepsy. Statistical significant difference was not found in genotype based analysis, allele frequency,
haplotype and combined genotype analysis.
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Introduction
Epilepsy is one of the most common neurological
disorders1. Despite advances in antiepileptic drug (AED)
therapy about one-third of patients with epilepsy are re-
sistant to drug treatment2. The consequences of uncon-
trolled epilepsy can be severe and include shortened life-
span, bodily injury, neuropsychological and psychiatric
impairment and social disability3. Most patients with re-
fractory epilepsy are resistant to several, if not all AEDs,
despite the fact that these drugs act by different mecha-
nisms2,4. This multidrug type of resistance could argue
against epilepsy-induced alterations in specific drug tar-
gets as the main cause of pharmacoresistant epilepsy
pointing instead to nonspecific and possibly adaptive
mechanisms4. It was found that gene polymorphism was
found that may influence the severity of disease in some
non-epileptic disorders5–7. Epilepsy was the first disorder
of central nervous system in which the drug resistance
was associated with enhanced expression of multidrug
transporters in the brain8. Multidrug transporters, such
as P-glycoprotein, multidrug resistance protein 1 (MRP1)
and multidrug resistance protein 2 (MRP2) and their
genes are overexpressed in capillary endothelial cells and
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astrocytes in epileptogenic brain tissue from patients
with medically intractable epilepsy9-13. The expression of
multidrug transporters in the astroglial end-feet cover-
ing the blood vessels that is found in epileptogenic brain
tissue might represent a 'second barrier' under these con-
ditions11,14. Several widely used AEDs, which have been
made lipophilic to allow them to penetrate the brain, are
substrates for Pgp and/or MRPs in the blood-brain bar-
rier8,15-21. Therefore, the overexpression of these trans-
porters in epileptogenic tissue is likely to reduce the
amount of drug that reaches the epileptic neurons. This
is one plausible explanation for multidrug resistance in
epilepsy4. Functional impact of polymorphisms in drug-
-efflux transporter genes can also contribute to multi-
drug resistance theory. Studies on ABCB1 gene gave con-
tradictory results and available data suggest that this
polymorphism may not directly cause altered Pgp trans-
port activity but may be associated with one or more
causal variants in the stretch of linkage disequilibrium
(LD) or is caused by multiple gene polymorphisms. Gene-
tic polymorphisms also occur frequently in other trans-
membrane transport systems including the MRPs22-24.
ABCC2 polymorphism 24C/T is associated with variable
pharmacokinetic parameters of mycophenolic acid, me-
thotrexate, irinotecan, diclofenac and toxic liver inju-
ry25-28 and for 1249 G/A ABCC2 polymorphism was found
to be associated with pharmacokinetics of tenofovir, tali-
nolol and toxic liver injury25,29,30. The aim of this re-
search was to investigate the possible association of
ABCC2 gene polymorphisms G1249A in exon 10 and
C24T in exon 1 with the development of drug resistance.
Patients and Methods
Patients
This cross-sectional study is a part of ongoing phar-
macogenomic study of epilepsy in Croatian population
and has been approved by the Ethics Committee of
Zagreb University Hospital Center. Patients were consec-
utively recruited through the Referral Epilepsy Center
Department of Neurology and genotyping was performed
in Department for Functional Genomics, Clinical Insti-
tute of Laboratory Diagnosis. All patients enrolled in the
study had an established diagnosis of partial complex ep-
ilepsy with or without secondary generalization and have
been suffering for more than two years. Non-lesional
brain MRI with epilepsy protocol was including criteria
and patients were in age between 16–66 years. They were
divided into two groups. The first group consisted of 52
patients refractory to the current therapy, while the sec-
ond group consisted of 45 patients with well-controlled
seizures. Refractory epilepsy was defined as one or more
seizures per month during last one year, with two or
more established AED at the maximally tolerated doses
in therapy. Patients with well-controlled seizures were
without seizures in same period. Compliance was deter-
mined by measuring concentration of anticonvulsants in
the serum. Seizure frequency was recorded from the pa-
tient's medical records, seizure diaries and patient inter-
view. Patients who were between these two groups were
excluded from the study. Patients with history of central
nervous system infection, head trauma, brain tumor,
cerebrovascular disease, neurodegenerative and psychi-
atric diseases, pseudo-attacks were excluded from the
study. All patients have signed informed consent to par-
ticipate in this study.
Non-responders took significantly higher number of
antiepileptics (c2=55.322, ss=4, p<0.001) 2.9, while re-
sponders took 1.9 antiepileptics. The mean age was 42.64
years (SD 13.91). Most of patients were taking one anti-
epileptic drug that is substrate of MRP2 (65% of non-re-
sponders, and 72% of responders). 30% of non-respond-
ers and 14% of responders were taking two antiepileptic
drugs that are substrates of MRP2. We did not find sig-
nificant difference in the mean number of antiepileptic
drugs in both groups (c2=5.345, ss=2, p>0.05). Carba-
mazepine was the most frequently administrated anti-
epileptic (95 patients – 88%), either as monotherapy or in
combination with other drugs. 54 (50.5%) patients were
using lamotrigine, 46 (43%) phenobarbital, 23 (21%)
valproate and 18 (16.8%) of patients were treated with
topiramate. Gabapentin and phenytoin were antiepilep-
tic drugs in 7 and 6 patients.
Methods
Genotyping of ABCC2-24C>T and 1249G>A was per-
formed by methods based on polymerase chain reaction
followed by restriction fragment length polymorphism
(PCR-RFLP), previously described by Mor-Cohen et al.31
and Naesen et al.28
Statistical analysis
A test for Hardy-Weinberg equilibrium using Markov
chain method32, as well as linkage-disequilibrium likeli-
hood-ratio test between loci whose gametic phase is
unknown33 were performed, as implemented in Arlequin
ver. 3.0134. Haplotype frequencies were estimated using
Expectation-Maximization algorithm implemented in the
same program, leading to maximum likelihood estimates
of haplotype frequency. c2-test was used for pair-wise
comparisons of the allele frequencies among groups. Log
likelihood ratio tests were performed to compare distri-
butions of the estimated haplotypes among groups, as
well as comparisons of genotype frequencies. P values of
less than 0.05 were considered statistically significant.
c2- or t-tests were performed for comparisons of duration
of epilepsy, antiepileptic drugs and MRP2 substrates be-
tween genotypes and between resistant vs. non resistant
patients. All statistical analyses were carried out using
SPSS 11.5 (SSPS inc., Chicago, IL, USA) statistical soft-
ware package. Pattern was calculated with Altman’s al-
gorithm and power of 80%.
Results
Genotype frequencies of the ABCC2 24CC, 24CT and
24TT in the sample were 47, 41 and 6 respectively and of
the ABCC2 1249GG, 1249AG and 1249AA genotypes
were 52, 35 and 10, respectively.
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No significant deviations from the expected Hardy-
-Weinberg proportions were observed in the total sample
(exon 1 C-24T: p=0.125; exon 10 G1249A: p=0.218), and
in resistant and non resistant patients. Test result for
linkage disequilibrium between loci was not found to be
significant (LD – c2=1.57, p<0.45, ss=2).
Pair-wise comparisons of the allele frequency between
resistant and non resistant patients did not revealed sta-
tistical differences for both loci (c2 test, exon 1 C-24T,
p=0.92; exon 10 G1249A, p=0.52). The same negative
results were found in genotype based analysis of exon 1
C-24T and exon 10 G1249A. Likelihood ratio, G test;
exon 1 C24T, p=0.683, Likelihood ratio G=0.854, ss=2;
exon 10 G1249A, p=0.606, Likelihood ratio G=1.246,
ss=2 (Table 1).
Likewise, no statistical differences were observed in
distributions of the estimated haplotypes between those
groups. Likelihood ratio G=0.3295; ss=3; p=0.954 (Ta-
ble 2), and in analyses of genotype combination frequen-
cies of ABCC2 24C>T and 1249G>A between subjects
who are resistant and non resistant to treatment. Likeli-
hood ratio G=3.447, ss= 3, p=0.651 (Table 3).
There were significant differences between resistant
and non resistant patients in the age of the onset of ill-
ness (X ages ± SD were 11.8 ± SD 6.37 vs. 23.4 ± SD
11.57, t=8,448, ss=105, p<0.001) in resistant and non
resistant patients, respectively and duration of illness (X
values ± SD were 30.4 ± SD 11.97 vs. 19.9 ± SD 11.59,
t=4,495, ss=105, p<0.001) in resistant and non resis-
tant group, respectively.
Discussion
ABCC2 gene encoded MRP2 transmembrane protein
may have a potential role in the modulation of brain pen-
etration of antiepileptic drugs17–21. We studied C24T and
G1249A polymorphisms of ABCC2 gene on exon 1 and 10
because they are the most common polymorphic variants
for which association with pharmacokinetics of some
cytostatic drugs was documented. Negative brain MRI
was including criteria because numerous clinical and
pathological factors can contribute to drug resistance in
symptomatic epilepsy, especially with pathological find-
ings of hippocampal sclerosis, cortical dysplasia, severe
brain injury, because they are more drug resistant than
idiopathic or cryptogenic epilepsy35. However, negative
MRI finding could not exclude the possibility that symp-
tomatic epileptogenic lesion known for causing phar-
macoresistance exists despite normal MRI because it can
depend on strength of machine.
Our data did not identify any significant association
between genetic polymorphisms of exon 1 24C>T and
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TABLE 1
DISTRIBUTION OF ALLELE AND GENOTYPE FREQUENCIES OF ABCC2 24C>T AND 1249G>A BETWEEN SUBJECTS WHO ARE
RESISTANT AND NON RESISTANT TO TREATMENT
Locus Resistant N=52 Non resistant N=45 OR (95%C.I.)
exon 1 C24T
aAllele
C 72 63 1.01 (0.84–1.20)
T 28 25 1
bGenotype
CC 26 21 1
CT 20 21 0.77 (0.33–1.78)
TT 4 2 1.62 (0.27–9.70)
exon 10 G1249A
aAllele
A 32 23 1.29 (0.76–1.90)
G 72 67 1
bGenotype
AA 7 3 1
GA 18 17 0.45 (0.10–2.05)
GG 27 25 0.46 (0.11–1.99)
a exon 1 -24C>T, p=0.920, c2 =0.01, SS=1; exon 10 1249G>A, p=0.52, c2=0.415, ss=1
b exon 1 -24C>T, p=0.683, Likelihood ratio G=0.854, ss=2; exon 10 1249G>A, p=0.606, Likelihood ratio G=1.246, ss=2
TABLE 2
DISTRIBUTION OF HAPLOTYPE FREQUENCIES OF ABCC2 24C>T AND 1249G>A BETWEEN SUBJECTS WHO ARE RESISTANT AND
NON RESISTANT TO TREATMENT
Haplotype C24T G1249A Resistant N=52 Non resistant N=45 OR (95%C.I.)
H1 C G 49.33 46.44 1
H2 C A 22.67 16.56 1.29 80.52–3.16)
H3 T G 21.67 18.56 1.09 (0.49–2.48)
H4 T A 6.33 6.44 0.93 (0.20–4.22)
Likelihood ratio G=0.3295; ss=3; p=0.954
exon 10 1249G>A of ABCC2 gene or any combined effect
in response to AED treatment. Statistical significant dif-
ference was not found in genotype based analysis, allele
frequency, haplotype and combined genotype analysis.
Several explanations are possible for this lack of associa-
tion. Phenytoin and carbamazepine are suggested as a
substrates of both Pgp and MRP2 and valproic acid is
suggested as a substrate of MRP216–18,21,35–37. Some ex-
perimental studies have doubted the fundamental facts
that most AEDs are substrates of ABC transporters38. Al-
though a number of AEDs have been identified as sub-
strates of ABC transporters in rodent models, recent ex-
perimental models have demonstrated significant
differences in the efflux transport of AEDs by ABC trans-
porters between species and have suggested that AEDs
are either not substrates or are very weak supstrates of
ABC transporters in humans39. Furthermore valproic
acid, as possible strongest antiepileptic substrate of
MRP2, is less effective in partial epilepsy than some
other antiepileptic drugs; carbamazepine, lamotrigine,
phenytoin, topiramate, etc40,41 and have minimal effect
in drug resistance in our group of patients.
The lack of association may be caused by overexpression
of transmembrane proteins (MRP2, MDR1) in blood-brain
barrier. Therefore, the overexpression of these transporters
in epileptogenic tissue is likely to reduce the amount of
drug that reaches the epileptic neurons and is also one
plausible explanation for multidrug resistance in epilepsy4.
Our results are in concordance with recent studies of
Seo et al.42, Kim et al.43, and Kwan et al.44 in which an as-
sociation between the ABCC2 genotypes or haplotypes
(including exon G1249A and exon C24T), and the re-
sponsiveness of AEDs was not found. Ufer M et al.45 eval-
uated the association of non-response to antiepileptic
pharmacotherapy with the frequency of variant alleles in
the drug transporter genes ABCB1 and ABCC2 or in the
CYP2C locus in young patients with epilepsy and an in-
dependent cohort of adults with drug-refractory epilepsy.
Results of the study confirmed that ABCC2 24C>T geno-
type did not affect hippocampal ABCC2 expression, but
was associated with increased ABCB1 expression, and in
conclusion data suggest a higher risk of antiepileptic
drug failure in ABCC2 24T allele carriers possibly be-
cause of compensatory upregulation of ABCB1. In all
studies the main problem was uniform determining of
drug resistance, small sample size and brain MRI posi-
tive etiology of epilepsy. Also in our study the main prob-
lem was small sample size.
In summary we did not identify significant associa-
tion of ABCC2 gene polymorphisms 1249A>G and
24C>T with the development of drug resistance in pa-
tients with cryptogenic partial complex epilepsy.
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NEDOSTATAK POVEZANOSTI POLIMORFIZMA GENA ABCC2 I TERAPIJSKOG ODGOVORA
NA ANTIEPILEPTIKE KOD BOLESNIKA SA EPILEPSIJOM U HRVATSKOJ
S A @ E T A K
Usprkos napretku koji je postignut u medikamentoznom lije~enju epilepsije, kod tre}ine bolesnika sa epilepsijom
napadaji nisu zadovoljavaju}e kontrolirani. Funkcionali utjecaj polimorfizma kod gena koji kodiraju transmembranske
transportere mo`e pridonijeti pojavi vi{estruke rezistencije na lijekove. Istra`ivanja ra|ena na ABCB1 genu pokazala
su kontradiktorne rezultate. Dosada{nje studije govore da polimorfizam gena mo`da izravno ne uzrokuje promjenu u
transportnoj aktivnosti P-glikoproteina (Pgp), nego bi mogao biti povezan sa jednom ili vi{e varijanti u {irokom podru-
~ju vezne neravnote`e, te mo`e biti uzrokovan i vi{estrukim genskim polimorfizmom. Genski polimorfizmi se u~estalo
pojavljuju i u ostalim transmenbranskim transportnim sustavima uklju~uju}i protein multirezistencije na lijekove
(MRP). Cilj ovog istra`ivanja je bio ispitati mogu}u povezanost polimorfizama gena ABCC2 G1249A eksona 10 i C24T
eksona 1 sa razvojem rezistencije na lijekove. Ovo presje~no istra`ivanje dio je farmakogenomskog istra`ivanja o epi-
lepsiji u hrvatskoj populaciji, a koje je jo{ u tijeku. Svi bolesnici koji su uklju~eni u ista`ivanje imali su postavljenu
dijagnozu kriptogene parcijalne epilepsije sa ili bez sekundarne generalizacije, a bolovali su du`e od dvije godine. Bo-
lesnici su bili podjeljeni u dvije skupine. Prvu skupinu ~inila su 52 bolesnika refrakterna na trenutnu terapiju dok je
drugu skupinu ~inilo 45 bolesnika sa zadovoljavaju}e kontroliranim napadajima. Rezultati ove studije ne potvr|uju
povezanost izme|u genskog polimorfizma eksona 1 (24C>T) i eksona 10 (1249G<A) ABCC2 gena ili njihovog zajed-
ni~kog utjecaja na u~inkovitost antiepilepti~ke terapije. Nije prona|ena statisti~ki zna~ajna razlika u genotipski bazi-
ranoj analazi, frekvenciji alela, haplotipskoj ili kombiniranoj genotipskoj analazi.
D. Spori{ et al.: ABCC2 Polymorphism and Drug-Resistant Epilepsy, Coll. Antropol. 37 (2013) 1: 41–45
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